A doctor has sobering news for Ohio residents suffering from mesothelioma. In a recent article, the doctor states that current mesothelioma research is showing little progress in its attempt to more successfully treat the fatal disease. The doctor claims that researchers need more funding and more efficient research planning to make any significant breakthroughs.
Mesothelioma is rare form of cancer that develops in the lungs. It is most often caused by asbestos exposure and is one of the leading drivers of asbestos litigation. The dangerous disease can develop decades after the initial exposure. In the article, the doctor states that researchers have identified various ways in which the disease progresses, but they don’t know which avenues are the most important to target or which avenues of progression are most likely in specific types of patients.
In the article, the doctor suggests that more studies are needed to test specific actions against various pathways in which the disease progresses. He argues that more trials utilizing randomness will help to identify which therapies are effective and which are useless. Those studies will require more funding, but they will also require more effective and efficient planning on the part of researchers.
Mesothelioma is a dangerous and often fatal form of cancer. In addition to the physical toll, victims of the disease can suffer significant costs for things like medical care, loss of work, decline in quality of life and pain and suffering. If the disease was caused by asbestos exposure, sufferers may be able to file a claim for damages. An attorney with experience in asbestos litigation could help a victim or victim’s family by examining the details of the disease and the exposure, filing all necessary claims and presenting the victim’s case in court. In the event of a settlement, the attorney could negotiate on behalf of the victim to obtain full and fair compensation.
Source: Asbestos Hub, “Sobering Assessment Of Mesothelioma Medical Research By Harvey Pass Offers Good Path For Going Forward With New Trials To Find Effective Therapies“, Tom Lamb, June 17, 2013